^{Photo: Tech in Asia}

Doximity’s Strategic Move Into AI-Powered Clinical Support

Doximity, widely known as the professional network for physicians, has taken a significant step to deepen its artificial intelligence offerings by acquiring Montreal-based startup Pathway Medical for $63 million. The acquisition aims to embed Pathway’s AI-driven clinical reference tools into Doximity’s platform, providing doctors with instant, evidence-based answers to clinical questions.

What Pathway Medical Brings to the Table

Pathway Medical’s AI solution synthesizes complex medical literature, guidelines, drug information, and clinical trials into concise, actionable insights. The startup boasts one of the largest structured datasets in medicine, which enables highly accurate responses to physician queries. Impressively, Pathway’s AI model scored 96% on the U.S. Medical Licensing Examination (USMLE) benchmark, a critical measure of medical knowledge proficiency.

Integration and Product Testing Underway

The acquisition deal, finalized in late July, includes $26 million in cash and up to $37 million in equity grants. Doximity CEO Jeff Tangney highlighted the company’s search for the best AI solution to assist physicians, noting that Pathway stood out — “and it wasn’t in Silicon Valley.”

Currently, the two companies are integrating their technologies and testing a combined AI product in beta with thousands of physicians, aiming to make Doximity the go-to platform not only for networking and telehealth but also for immediate clinical decision support.

Expanding Doximity’s AI Ecosystem

Doximity already offers AI tools such as Doximity GPT, which helps doctors generate insurance letters and summarize patient charts. Pathway Medical’s rich dataset will add significant “robustness” to Doximity’s AI backend, according to Dr. Amit Phull, Chief Clinical Experience Officer at Doximity. The enhanced data ties together dosages, clinical guidelines, medical literature, and citations to improve the precision and reliability of AI-powered recommendations.

AI in Healthcare: Growing Demand and Challenges

The acquisition comes amid a broader surge in healthcare-related AI inquiries. OpenAI CEO Sam Altman recently noted that health queries are among the largest use cases for ChatGPT, with the latest GPT-5 model offering improved accuracy in this critical domain. While patients increasingly rely on AI tools for health questions, medical professionals require AI that delivers vetted, trustworthy information — a gap Doximity aims to fill with Pathway’s technology.

Financial Momentum and Market Impact

Since going public in 2021, Doximity has gained strong market traction, with its stock rising about 10% in 2025, following a 90% jump in 2024. The company currently commands a market capitalization near $11 billion.

Doximity’s fiscal first-quarter results, reported on Thursday, outpaced expectations: revenue climbed 15% year-over-year to $145.9 million, surpassing analyst forecasts of $139.5 million. Earnings per share reached 36 cents, beating the consensus estimate of 30 cents. Following these strong results, Doximity shares gained approximately 6% in after-hours trading.

Looking Ahead: AI-Driven Clinical Excellence

With the Pathway Medical acquisition, Doximity is poised to elevate its platform from a professional network to a comprehensive clinical resource powered by AI. By offering faster, evidence-based answers at physicians’ fingertips, Doximity aims to improve patient care quality while supporting doctors in an increasingly complex medical landscape.

‍